Sample Business Contracts

First Supplemental Indenture - ICN Pharmaceuticals Inc., SPI Pharmaceuticals Inc. and Citibank NA

Sponsored Links


         FIRST SUPPLEMENT TO INDENTURE, dated as of October 14, 1994 between
ICN Pharmaceuticals, Inc. (the "Company"), ICN Merger Corp., a Delaware
corporation and a wholly-owned subsidiary of SPI Pharmaceuticals, Inc. ("New
ICN"), and Citibank, N.A., as trustee (the "Trustee"), under the Indenture
hereinafter mentioned.


         The Company has executed and delivered an indenture (the "Indenture"),
dated as of October 30, 1986, between the Company and the Trustee pursuant to
which the Company issued $75,000,000 aggregate principal amount of 6-3/4%
Subordinated Convertible Bonds due 2001 (the "Securities").  Each Security is
exchangeable for common stock, $1.00 par value, of ICN (the "ICN Common Stock")
at a conversion price, immediately prior to the Merger (as defined herein), of
$20.68 (the "Conversion Price").  On the date hereof, Bonds in an aggregate
principal amount of $449,000 remain outstanding.

         In accordance with Section 701 of the Indenture and pursuant to
resolutions of the Board of Directors of the Company and New ICN, the Company
and New ICN desire to evidence the merger (the "Merger") of the Company and
certain of its affiliates with and into New ICN, pursuant to which New ICN
shall be the surviving corporation, and New ICN's assumption of the Company's
obligations under the Indenture.  Upon the effectiveness of the Merger, New ICN
will change its name to ICN Pharmaceuticals, Inc.

for and in consideration of the premises and in order to comply with Section
701 of the Indenture, the Company and New ICN hereby covenant and agree with
the Trustee as follows:

         1.      Assumption.  Upon the effectiveness of this First Supplemental
Indenture and without further action by the parties hereto, New ICN will
succeed to the Company under the Indenture and assume the due and punctual
payment of the principal of (and premium, if any) and interest (including all
additional interest payable pursuant to Section 1004 of the Indenture) on all
the Securities, and the performance of every covenant of the Indenture on the
part of the Company to be performed or observed.

         2.      Conversion.  In compliance with Section 1211 of the Indenture,
on and after the date hereof until October 30, 2001, the holder of each
Security shall be entitled to receive upon exchange of his or her Bond in lieu
of each share of ICN Common Stock deliverable to such holder immediately prior
to the date hereof, 0.512 shares of common stock, $.01 par value of New ICN
("New ICN Common Stock") at the Conversion Price of $20.68 for such 0.512
shares of New ICN Common Stock.

         3.      Waiver:  New ICN hereby expressly waives any right to redeem
the Securities under circumstances in which the Company would not have been
entitled to redeem the Securities if it had remained the obligor thereon.

         4.      Covenants.  Prior to the effectiveness of the Merger, the
Company shall deliver to the Trustee an Officers' Certificate and an Opinion of
Counsel each stating that the Merger and this Supplemental Indenture comply
with Article 7 of the Indenture and that all conditions precedent therein
provided for relating to the Merger have been complied with and that this First
Supplemental Indenture is authorized by the Indenture.

         5.      Effectiveness.  This First Supplemental Indenture shall be
deemed to be effective immediately upon the filing of the Certificate of Merger
merging the Company and its affiliates into New ICN with the Secretary of State
of the State of Delaware.

         6.      Instruments to Be Read Together.  This First Supplemental
Indenture is an indenture supplemental to and in implementation of the
Indenture, and said Indenture and this First Supplemental Indenture shall
henceforth be read together.

<PAGE>   2
         7.      Acceptance by Trustee.  The Trustee accepts, upon the terms
and conditions set forth in the Indenture, the amendment of the Indenture
hereby affected.  Without limiting the generality of the foregoing, the Trustee
assumes no responsibility for the correctness of the recitals of fact contained
herein, which shall be taken as statements of the Company and New ICN: and the
Trustee makes no representations and shall have no responsibility as to the
validity of this First Supplemental Indenture, except as expressly set forth in
the Indenture.  The Indenture as amended and supplemented by this First
Supplemental Indenture is in all respects confirmed and preserved.

         8.      Terms Defined.  All terms defined elsewhere in the Indenture
have the same meanings herein.

         9.      Counterparts.  This First Supplemental Indenture my be
executed in any number of counterparts, each of which so executed shall be
deemed to be an original, but all such counterparts shall together constitute
but one and the same instrument.

         10.     Governing Law.  This First Supplemental Indenture shall be
construed in accordance with and governed by the laws of the State of New York.

         IN WITNESS WHEREOF, the parties hereto have caused this First
Supplemental Indenture to be duly executed, all as of the date and year first
above written.

                                       ICN PHARMACEUTICALS, INC.

                                           Name:   John E. Giordani
                                           Title:  Executive Vice President and
                                                   Chief Financial Officer

                                       ICN MERGER CORP.

                                           Name:   John E.Giordani
                                           Title:  Director and Vice President

                                       CITIBANK, N.A.